title: Naloxone reversal of oxymorphone effects in dogs.
abstract: Oxymorphone was administered IV to dogs 4 times at 20-minute intervals (total dosage, 1 mg/kg of body weight, IV) on 2 separate occasions. Minute ventilation, mixed-expired carbon dioxide concentration, arterial and mixed-venous pH and blood gas tensions, arterial, central venous, pulmonary arterial, and pulmonary wedge pressures, and cardiac output were measured. Physiologic dead space, base deficit, oxygen transport, and vascular resistance were calculated before and at 5 minutes after the first dose of oxymorphone (0.4 mg/kg) and at 15 minutes after the first and the 3 subsequent doses of oxymorphone (0.2 mg/kg). During 1 of the 2 experiments in each dog, naloxone was administered 20 minutes after the last dose of oxymorphone; during the alternate experiment, naloxone was not administered. In 5 dogs, naloxone was administered IV in titrated dosages (0.005 mg/kg) at 1-minute intervals until the dogs were able to maintain sternal recumbency, and in the other 5 dogs, naloxone was administered IM as a single dose (0.04 mg/kg). Naloxone (0.01 mg/kg, IV or 0.04 mg/kg, IM) transiently reversed most of the effects of oxymorphone. Within 20 to 40 minutes after IV naloxone administration and within 40 to 70 minutes after IM naloxone administration, most variables returned to the approximate values measured before naloxone administration. The effects of oxymorphone outlasted the effects of naloxone; cardiovascular and pulmonary depression and sedation recurred in all dogs. Four hours and 20 minutes after the last dose of oxymorphone, alertness, responsiveness, and coordination improved in all dogs after IM administration of naloxone. Cardiac arrhythmia, hypertension, or excitement was not observed after naloxone administration.
authors: Department of Surgery, School of Veterinary Medicine, University of California, Davis 95616.
authors: V S
authors: VS
authors: Copland
authors: S C
authors: SC
authors: Haskins
authors: J
authors: J
authors: Patz
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D002302:Cardiac Output / Q000187:drug effects; D004285:Dogs / Q000097:blood / Q000502:physiology*; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D004091:Hydromorphone / Q000031:analogs & derivatives*; D009270:Naloxone / Q000009:adverse effects / Q000494:pharmacology*; D010100:Oxygen / Q000097:blood; D010111:Oxymorphone / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D012119:Respiration / Q000187:drug effects*; D013990:Tidal Volume / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D002245:Carbon Dioxide; D009270:Naloxone; D010111:Oxymorphone; D004091:Hydromorphone; D010100:Oxygen